Who Owns Coherus Biosciences Company?

Coherus Biosciences Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Coherus Biosciences?

Unraveling the ownership structure of Coherus Biosciences is key to understanding its future. With a strategic pivot towards innovative oncology, driven by the recent divestiture of its UDENYCA franchise, the question of who controls Coherus becomes even more critical. This shift, finalized on April 11, 2025, significantly impacts the company's trajectory and the interests of Coherus Biosciences SWOT Analysis investors.

Understanding the Coherus ownership landscape provides crucial insights for anyone tracking Coherus stock. From its inception in 2010 as BioGenerics, Inc., to its evolution into an innovative oncology player, the company's ownership has undergone significant changes. This analysis will delve into the major shareholders, the influence of Coherus management, and the impact of recent strategic decisions on the company's future, including its product pipeline and the interests of Coherus investors.

Coherus BioSciences was established by a group of biotech experts, including Denny Lanfear and Doug Treat. Denny Lanfear currently holds the positions of Chairman and Chief Executive Officer. The founders' vision was to create a company focused on delivering high-quality biosimilar therapeutics to improve patient access globally. This strategic direction has shaped the company's early development and its approach to the market.

Early financial backing played a crucial role in the initial phases of Coherus BioSciences. The company's ability to secure funding was essential for its operational and developmental activities. This early financial support, along with a collaborative business model, was instrumental in shaping Coherus's early ownership structure and growth trajectory.

The company's initial capitalization benefited significantly from early investors and backers. The early financial support and the collaborative business model, which aligned service providers through ownership and shared incentives, were instrumental in shaping Coherus's early ownership and growth trajectory. Specific equity splits or shareholding percentages at the company's inception are not publicly detailed in the available information.

Early Funding and Investors

In 2011, Coherus BioSciences completed a Series A financing round, successfully raising $55 million. This funding was crucial for the company's early operations and research and development activities.

Equity and Licensing

By May 2014, Coherus had raised over $220 million from equity and non-dilutive licensing fees and milestones. This substantial funding demonstrates the confidence investors had in the company's potential.

Series C Financing

The Series C financing round in May 2014 attracted new investors, including KKR & Co. L.P., Venrock, RA Capital Management, Rock Springs Capital, and Fidelity Biosciences. These investors joined existing backers Sofinnova Ventures, Lilly Ventures, and Vivo Capital.

Key Leadership

Denny Lanfear, a co-founder, currently serves as the Chairman and CEO of Coherus BioSciences. His leadership has been pivotal in guiding the company's strategic direction and operational execution.

Focus and Mission

Coherus BioSciences focuses on delivering high-quality biosimilar therapeutics. This focus aims to expand patient access to essential medicines globally, reflecting the company's commitment to improving healthcare outcomes.

Ownership Structure

The early ownership structure of Coherus BioSciences was shaped by a combination of founder contributions and investments from various venture capital firms and institutional investors. The exact equity distribution at the company's inception is not publicly available.

The early success of Coherus BioSciences in securing funding and attracting key investors highlights the company's potential and the confidence placed in its mission. For more detailed insights into the company's financial operations and business model, you can refer to Revenue Streams & Business Model of Coherus Biosciences.

Coherus Biosciences SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Coherus Biosciences has seen significant evolution, especially with its strategic pivot toward oncology. As a publicly traded company on Nasdaq under the ticker CHRS, understanding its ownership is crucial for investors and stakeholders. The company's strategic decisions, including asset divestitures, have reshaped its financial position and future direction, influencing who owns Coherus and the company's overall trajectory.

Major shifts in Coherus ownership are directly linked to its strategic moves. The divestiture of the UDENYCA franchise to Intas Pharmaceuticals Ltd., finalized on April 11, 2025, is a prime example. This transaction, valued at up to $558.4 million, significantly impacted Coherus's financial standing and strategic focus. The sales of CIMERLI to Sandoz in January 2024 for $170 million and YUSIMRY to Hong Kong King-Friend Industrial in June 2024 for $40 million further illustrate this shift away from biosimilars. These changes have led to a projected post-divestiture cash balance of approximately $250 million, extending the company's cash runway into 2027. Additionally, the company's headcount is expected to be reduced by approximately 30% to around 155 employees following the UDENYCA transaction.

Institutional ownership plays a significant role in Coherus's structure. As of March 2025, there were 239 institutional owners and shareholders, holding a total of 70,447,784 shares. The Vanguard Group Inc. and BlackRock, Inc. each hold approximately 11 million shares. Tang Capital Management LLC holds 5.1 million shares. Rubric Capital Management LP reduced its position by 49% to 5.3 million shares by December 2024. These major shareholders, along with others like Kohlberg Kravis Roberts & Co, Millennium Management, Geode Capital Management, and State Street Corporation, significantly influence the company's direction. For more details on the company's performance, you can refer to this article about Coherus Biosciences.

Key Ownership Details

Coherus Biosciences is a publicly traded company with substantial institutional ownership.

• Vanguard Group Inc. and BlackRock, Inc. are major institutional shareholders.
• Strategic divestitures have significantly impacted the company's financial position and focus.
• The company's cash runway is extended into 2027 due to recent transactions.
• The company's headcount is expected to be reduced by approximately 30% following the UDENYCA transaction.

Coherus Biosciences PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Coherus BioSciences plays a crucial role in guiding the company's strategy and overseeing its operations. While specific details about current board members, their affiliations with major shareholders, or founder stakes are not readily available in recent search results for 2024-2025, the company's filings with the Securities and Exchange Commission (SEC) offer insights into its governance structure. For example, the definitive proxy statement on Schedule 14A, filed on January 28, 2025, provides comprehensive information on voting matters.

A Special Meeting of stockholders was held on March 11, 2025, where important proposals were voted on, including the divestiture of the UDENYCA franchise. Understanding the composition and influence of the board is key for Coherus investors and anyone interested in Brief History of Coherus Biosciences.

The voting structure for the company's common stock is based on a one-share-one-vote system. At the Special Meeting, stockholders approved the UDENYCA divestiture, demonstrating the influence of shareholder voting on significant corporate decisions. Detailed information on the voting results and other matters discussed at the meeting can be found in the company's SEC filings.

Coherus Biosciences Board and Voting

The Board of Directors at Coherus Biosciences oversees the company's strategic direction. The company's proxy statements contain detailed information on board members and voting matters.

• The company held a Special Meeting on March 11, 2025.
• Stockholders voted on proposals, including the UDENYCA divestiture.
• As of January 27, 2025, there were 115,890,186 shares outstanding.
• The company uses a one-share-one-vote structure.

Coherus Biosciences Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership structure of Coherus Biosciences has seen substantial shifts. These changes are largely due to strategic divestitures and a refocus on oncology. A key development is the April 11, 2025, completion of the UDENYCA franchise sale to Intas Pharmaceuticals Ltd. for up to $558.4 million. This, coupled with the sales of CIMERLI in January 2024 for $170 million and YUSIMRY in June 2024 for $40 million, marks the company's exit from the biosimilar market. These actions have significantly reshaped the financial landscape of the company.

These divestitures have had a considerable impact on the financial health of the company. As a result, Coherus anticipates a post-close cash balance of around $250 million, extending its cash runway into 2027. Denny Lanfear, Chairman and Chief Executive Officer, described 2024 as a year of transformation into an innovative oncology company. This strategic pivot has also led to a reduction in headcount by approximately 30%, bringing the employee count to about 155. The company's annual net revenue increased by 4% to $267.0 million in 2024, despite these divestitures. Coherus is now concentrating on its innovative novel oncology programs, including LOQTORZI, casdozokitug, and CHS-114, and plans for future label expansions through capital-efficient external partnerships. For more insights, consider exploring the Competitors Landscape of Coherus Biosciences.

Institutional ownership remains a key aspect of Coherus ownership. As of March 2025, major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and Tang Capital Management LLC. While some institutional investors reduced their stakes in late 2024, others, like Point72 Asset Management, L.P., increased their holdings during the same period. This indicates a dynamic investment environment as the company adjusts its strategic focus. The company's leadership team is steering the company toward a novel oncology future.

Coherus Ownership Overview

The ownership structure of Coherus Biosciences has evolved significantly.

Key Institutional Investors

Vanguard, BlackRock, and Tang Capital Management are among the largest.

Strategic Shifts

The company is focusing on oncology and divesting biosimilar assets.

Financial Impact

Divestitures have led to a strengthened cash position and extended runway.

Coherus Biosciences Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs